- Report
- October 2024
- 182 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- April 2025
- 193 Pages
Global
From €4692EUR$4,950USD£3,920GBP
- Report
- March 2025
- 294 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- December 2024
- 175 Pages
Global
From €3791EUR$4,000USD£3,167GBP
- Report
- March 2025
- 192 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- October 2024
- 200 Pages
Global
From €3554EUR$3,750USD£2,969GBP
- Report
- October 2023
- 150 Pages
Global
From €4597EUR$4,850USD£3,840GBP
From €2370EUR$2,500USD£1,980GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Drug Pipelines
- January 2018
- 18 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Report
- February 2024
- 104 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Book
- October 2012
- 1570 Pages
The Dengue Vaccine market is a subset of the larger Vaccines market. Dengue is a mosquito-borne virus that can cause severe flu-like symptoms and can be fatal in some cases. Vaccines are the most effective way to prevent dengue infection. The Dengue Vaccine market is composed of a variety of products, including live attenuated vaccines, inactivated vaccines, and recombinant vaccines. These products are used to protect against all four serotypes of the dengue virus.
The Dengue Vaccine market is highly competitive, with many companies vying for market share. Companies in the market include Sanofi Pasteur, Merck, GlaxoSmithKline, Takeda, and Bharat Biotech. These companies are actively developing and marketing dengue vaccines to meet the growing demand for protection against the virus. Show Less Read more
